Sonia Chopra, MD
Urology · Florence, KYNPI 1598927345
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,255 of the $9,372 with a category attached, or 66.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.7%.
Across 271 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$2K
- Medtronic$2K
- Calyxo, Inc.$1K
- Astellas Pharma US Inc$810
- C. R. Bard, Inc. & Subsidiaries$379
- Teleflex LLC$378
- plus $3K from 34 others
What the payments were for
- Travel & lodging$2,93731%
- Food & beverage$6,25567%
- Education$1802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 9 | $1,936 |
| Medtronic(2 entities) | 43 | $1,827 |
| Calyxo, Inc. | 6 | $1,225 |
| Astellas Pharma US Inc | 48 | $810 |
| C. R. Bard, Inc. & Subsidiaries | 23 | $379 |
| Teleflex LLC | 3 | $378 |
| AbbVie(2 entities) | 22 | $334 |
| Coloplast | 6 | $255 |
| Rochester Medical Corporation | 23 | $249 |
| Johnson & Johnson | 5 | $187 |
| Sumitomo Pharma America, Inc. | 10 | $168 |
| Urogen Pharma, Inc. | 5 | $145 |
| Axonics, Inc. | 3 | $145 |
| Endo Pharmaceuticals Inc. | 7 | $141 |
| Ferring Pharmaceuticals Inc. | 6 | $128 |
| Boston Scientific | 2 | $125 |
| Angiodynamics, Inc. | 3 | $114 |
| Myovant Sciences Inc. | 5 | $90 |
| Olympus America Inc. | 5 | $84 |
| Amgen | 4 | $61 |
| Antares Pharma, Inc. | 3 | $57 |
| Duchesnay USA Incorporated | 3 | $53 |
| Bayer | 3 | $47 |
| Merck | 2 | $40 |
| Pfizer | 3 | $36 |
| Dendreon Pharmaceuticals LLC | 2 | $35 |
| Laborie Medical Technologies Corp. | 2 | $34 |
| Urovant Sciences Inc | 2 | $34 |
| Innovation Technologies Inc | 1 | $29 |
| Civco Medical Instruments | 1 | $29 |
| Therapeuticsmd, Inc. | 2 | $26 |
| EDAP Technomed Inc | 1 | $24 |
| Endo USA, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Photocure Inc | 1 | $19 |
| Dornier Medtech America, Inc | 1 | $17 |
| Smith+Nephew | 1 | $17 |
| Blue Earth Diagnostics | 1 | $16 |
| Dentsply IH Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,180
- CVAC Aspiration System$1,225
- INTERSTIM$758
- Erleada$119
- Porges Coloplast$118
- Axonics$117
How this compares
$9,372 in reported general payments places this provider in the 85th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 83 | $89,096 |
| GemtesaVibegron | 14 | $13,244 |
| Estradiol | 49 | $2,797 |
| Tamsulosin Hcl | 175 | $2,310 |
| Trimethoprim | 25 | $1,850 |
| Finasteride | 113 | $1,227 |
| NitrofurantoinNitrofurantoin Macrocrystal | 29 | $618 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $387 |
| Cephalexin | 71 | $345 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $163 |
| Ciprofloxacin Hcl | 13 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $810 | $89,09683 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $168 | $13,24414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 urology providers in Kentucky.
Other urology in Florence
- Balaji KalyanaramanFlorence$7K
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
- Stephen MonnigLexington$18K
- Kellen ChoiLouisville$17K
- Rosa ParkLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.